1. Moustou AE, Matekovits A, Dessinioti C, Antoniou C, Sfikakis PP, Stratigos AJ. Cutaneous side effects of antitumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol. 2009; 61:486–504.
Article
2. Hahn HJ, Jung JW, Park HJ, Lee YW, Choe YB, Ahn KJ. A case of psoriasiform dermatitis following adalimumab injection for treatment of ankylosing spondylitis. Korean J Dermatol. 2013; 51:743–5.
3. Kim JY, Choi M, Cho KH. A case of pustular psoriasis developed during infliximab treatment for crohn's disease. Korean J Dermatol. 2012; 50:810–3.
4. Park HY, Kim HS, Hong R. A case of bowen's disease during adalimumab treatment for Felty's syndrome. Korean J Med. 2012; 83:400–4.
Article
5. Kim JH, Shin WU, Baek YS, Oh CH, Kim JH. Etanercept-induced Leukocytoclastic Vasculitis. Korean J Dermatol. 2012; 50:807–9.
6. Jung WJ, Nam YJ, Lee SG, Kim JM, Song M, Kim MB, et al. Henoch-Schonlein purpura in a patient with ankylosing spondylitis after infliximab therapy. Korean J Med. 2013; 84:764–8.
7. Lobel EZ, Korelitz BI, Warman JI. Red man syndrome and infliximab. J Clin Gastroenterol. 2003; 36:186.
Article
8. Persley KM. Infliximab infusion reactions: desensitizing ourselves to the danger. Inflamm Bowel Dis. 2004; 10:62–3.
Article
9. Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, et al. Influence of immunogenicity on the longterm efficacy of infliximab in Crohn's disease. N Engl J Med. 2003; 348:601–8.
Article
10. Han PD, Cohen RD. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease. Drugs. 2004; 64:1767–77.
11. Baidoo L, Lichtenstein GR. What next after infliximab? Am J Gastroenterol. 2005; 100:80–3.
Article
12. Werth VP, Levinson AI. Etanercept-induced injection site reactions: mechanistic insights from clinical findings and immunohistochemistry. Arch Dermatol. 2001; 137:953–5.
13. Zeltser R, Valle L, Tanck C, Holyst MM, Ritchlin C, Gaspari AA. Clinical, histological, and immunophe-notypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein. Arch Dermatol. 2001; 137:893–9.
14. Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label ex-tension study. J Am Acad Dermatol. 2006; 55:598–606.
Article
15. Gonzá lez-López MA, Martínez-Taboada VM, González-Vela MC, Blanco R, Fernández-Llaca H, Rodríguez-Valverde V, et al. Recall injection-site reactions associated with etanercept therapy: report of two new cases with immunohistochemical analysis. Clin Exp Dermatol. 2007; 32:672–4.
Article
16. Wollina U, Hansel G, Koch A, Schönlebe J, Köstler E, Haroske G. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol. 2008; 9:1–14.
17. Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, et al. British Society for Rheumatology Biologics Register Control Centre Consortium; BSRBR. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2009; 68:209–15.
18. Cohen JD, Bournerias I, Buffard V, Paufler A, Chevalier X, Bagot M, et al. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series. J Rheumatol. 2007; 34:380–5.
19. Nestle FO, Gilliet M. Defining upstream elements of psoriasis pathogenesis: an emerging role for interferon alpha. J Invest Dermatol. 2005; 125:xiv–xv.
20. Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci U S A. 2005; 102:3372–7.
21. Verea MM, Del Pozo J, Yebra-Pimentel MT, Porta A, Fonseca E. Psoriasiform eruption induced by infliximab. Ann Pharmacother. 2004; 38:54–7.
Article
22. Seneschal J, Lepreux S, Bouyssou-Gauthier ML, Heliot-Hosten I, Economou A, Dehais J, et al. Psoriasiform drug eruptions under anti-TNF treatment of arthritis are not true psoriasis. Acta Derm Venereol. 2007; 87:77–80.
Article
23. Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by antitumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum. 2005; 52:2513–8.
Article
24. Takahashi H, Hashimoto Y, Ishida-Yamamoto A, Ashida T, Kohgo Y, Iizuka H. Psoriasiform and pustular eruption induced by infliximab. J Dermatol. 2007; 34:468–72.
Article
25. Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005; 7:R666–76.
26. Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Röwert J, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol. 2007; 156:486–91.
27. Vestergaard C, Deleuran M, Kragballe K. Two cases of atopic dermatitis-like conditions induced in psoriasis patients treated with infliximab. J Eur Acad Dermatol Venereol. 2007; 21:1272–4.
Article
28. Mangge H, Gindl S, Kenzian H, Schauenstein K. Atopic dermatitis as a side effect of antitumor necrosis factor-alpha therapy. J Rheumatol. 2003; 30:2506–7.
29. Ladizinski B, Lee KC. Infliximab-Induced Urticaria. J Emerg Med. 2014; [Epub ahead of print].
Article
30. Corominas H, Sánchez-Eslava L, García G, Padró I, Aimarich C, Gonzàlez J, et al. Safety profile of biological intravenous therapy in a rheumatoid arthritis patients cohort. Clinical nursing monitoring (Sebiol study). Reumatol Clin. 2013; 9:80–4.
Article
31. Puxeddu I, Giori L, Rocchi V, Bazzichi L, Bombardieri S, Tavoni A, et al. Hypersensitivity reactions during treatment with infliximab, etanercept, and adalimumab. Ann Allergy Asthma Immunol. 2012; 108:123–4.
Article
32. Habal F, Huang V. Angioedema associated with Crohn's disease: response to biologics. World J Gastroenterol. 2012; 18:4787–90.
Article
33. Wilson LH, Eliason MJ, Leiferman KM, Hull CM, Powell DL. Treatment of refractory chronic urticaria with tumor necrosis factor-alfa inhibitors. J Am Acad Dermatol. 2011; 64:1221–2.
Article
34. Atzeni F, Turiel M, Capsoni F, Doria A, Meroni P, Sarzi-Puttini P. Autoimmunity and anti-TNF-alpha agents. Ann N Y Acad Sci. 2005; 1051; 559–69.
35. Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004; 51:534–42.
Article
36. Poulalhon N, Begon E, Lebbé C, Lioté F, Lahfa M, Bengoufa D, et al. A followup study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br J Dermatol. 2007; 156:329–36.
Article
37. De Bandt M, Sibilia J, Le Loët X, Prouzeau S, Fautrel B, Marcelli C, et al. Club Rhumatismes et Inflammation. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther. 2005; 7:R545–51.
Article
38. Mohan N, Edwards ET, Cupps TR, Slifman N, Lee JH, Siegel JN, et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol. 2004; 31:1955–8.
39. Ramos-Casals M, Brito-Zerón P, Muñoz S, Soria N, Galiana D, Bertolaccini L, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007; 86:242–51.
40. Lebas D, Staumont-Sallé D, Solau-Gervais E, Flipo RM, Delaporte E. Cutaneous manifestations during treatment with TNF-alpha blockers: 11 cases. Ann Dermatol Venereol. 2007; 134:337–42.
41. Badgwell C, Rosen T. Cutaneous sarcoidosis therapy updated. J Am Acad Dermatol. 2007; 56:69–83.
Article
42. Callejas-Rubio JL, Ortego-Centeno N, Lopez-Perez L, Benticuaga MN. Treatment of therapy-resistant sarcoidosis with adalimumab. Clin Rheumatol. 2006; 25:596–7.
Article
43. Utz JP, Limper AH, Kalra S, Specks U, Scott JP, Vuk-Pavlovic Z, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest. 2003; 124:177–85.
Article
44. Gonzá lez-López MA, Blanco R, González-Vela MC, Fernández-Llaca H, Rodríguez-Valverde V. Development of sarcoidosis during etanercept therapy. Arthritis Rheum. 2006; 55:817–20.
Article
45. Peno-Green L, Lluberas G, Kingsley T, Brantley S. Lung injury linked to etanercept therapy. Chest. 2002; 122:1858–60.
Article
46. Bremner R, Simpson E, White CR, Morrison L, Deodhar A. Palisaded neutrophilic and granulomatous dermatitis: an unusual cutaneous manifestation of immune-mediated disorders. Semin Arthritis Rheum. 2004; 34:610–6.
Article
47. Deng A, Harvey V, Sina B, Strobel D, Badros A, Junkins-Hopkins JM, et al. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors. Arch Dermatol. 2006; 142:198–202.
Article
48. Voulgari PV, Markatseli TE, Exarchou SA, Zioga A, Drosos AA. Granuloma annulare induced by anti-tumour necrosis factor therapy. Ann Rheum Dis. 2008; 67:567–70.
Article
49. El Shabrawi-Caelen L, La Placa M, Vincenzi C, Haidn T, Muellegger R, Tosti A. Adalimumab-induced psoriasis of the scalp with diffuse alopecia: a severe potentially ir-reversible cutaneous side effect of TNF-alpha blockers. Inflamm Bowel Dis. 2010; 16:182–3.
Article
50. Moran GW, Lim AW, Bailey JL, Dubeau MF, Leung Y, Devlin SM, et al. Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2013; 38:1002–24.
Article
51. Richardson SK, Gelfand JM. Immunobiologicals, cyto-kines, and growth factors in dermatology. Goldsmith LA, Fitzpatrick TB, editors. Fitzpatrick's dermatology in general medicine. 8th ed.p. 2819–22. New York: McGraw-Hill Medical;2012.
52. Salliot C, Gossec L, Ruyssen-Witrand A, Luc M, Duclos M, Guignard S, et al. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford). 2007; 46:327–34.
53. Kim SY, Solomon DH. Tumor necrosis factor blockade and the risk of viral infection. Nat Rev Rheumatol. 2010; 6:165–74.
Article
54. Sanz-Sánchez T, Daudén E, González-Arribas A, Garcí a-Díez A. Sudden onset of viral warts during treatment with etanercept. Actas Dermosifiliogr. 2010; 101:460–2.
Article
55. Alpayci M. Exacerbation of verruca vulgaris associated with etanercept in a case of ankylosing spondylitis. Turk J Phys Med Rehab. 2013; 59:169.
56. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving antitumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006; 54:2368–76.
Article
57. Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005; 52:3403–12.
Article
58. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002; 46:2287–93.
Article
59. Mahé E, Descamps V, Grossin M, Fraitag S, Crickx B. CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab. Br J Dermatol. 2003; 149:170–3.
Article
60. Adams AE, Zwicker J, Curiel C, Kadin ME, Falchuk KR, Drews R, et al. Aggressive cutaneous T-cell lymphomas after TNFalpha blockade. J Am Acad Dermatol. 2004; 51:660–2.
61. Sanli H, Ataman S, Akay BN, Yilmaz A, Yildizlar D, Gürgey E. Mycosis fungoides in a patient with ankylosing spondylitis during infliximab therapy. J Drugs Dermatol. 2007; 6:834–6.
62. Wolfe F, Michaud K. The effect of methotrexate and antitumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum. 2007; 56:1433–9.
Article
63. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat. 2004; 15:280–94.
Article
64. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002; 46:3151–8.
Article
65. Klareskog L, Gaubitz M, Rodriguez-Valverde V, Malaise M, Dougados M, Wajdula J. Etanercept Study 301 Investigators. A longterm, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs. Ann Rheum Dis. 2006; 65:1578–84.
Article
66. Lebwohl M, Blum R, Berkowitz E, Kim D, Zitnik R, Osteen C, et al. No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years. Arch Dermatol. 2005; 141:861–4.
Article
67. Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med. 1999; 5:828–31.
68. Penn I. Malignant melanoma in organ allograft recipients. Transplantation. 1996; 61:274–8.
69. Jensen P, Hansen S, M⊘ller B, Leivestad T, Pfeffer P, Geiran O, et al. Skin cancer in kidney and heart transplant recipients and different longterm immunosuppressive therapy regimens. J Am Acad Dermatol. 1999; 40:177–86.
Article
70. Hollenbeak CS, Todd MM, Billingsley EM, Harper G, Dyer AM, Lengerich EJ. Increased incidence of melanoma in renal transplantation recipients. Cancer. 2005; 104:1962–7.
Article
71. Le Mire L, Hollowood K, Gray D, Bordea C, Wojnarowska F. Melanomas in renal transplant recipients. Br J Dermatol. 2006; 154:472–7.
Article
72. Fulchiero GJ Jr, Salvaggio H, Drabick JJ, Staveley-O'Carroll K, Billingsley EM, Marks JG, et al. Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies. J Am Acad Dermatol. 2007; 56(5 Suppl):S65–7.
Article
73. Bovenschen HJ, Tjioe M, Vermaat H, de Hoop D, Witteman BM, Janssens RW, et al. Induction of eruptive benign melanocytic naevi by immune suppressive agents, including biologicals. Br J Dermatol. 2006; 154:880–4.
Article